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The introduction of endovascular aneurysm repair (EVAR) (1) has revolutionized the treatment of the abdominal aortic aneurysm (AAA), becoming the first-line approach in most centers. Since the initial experience with EVAR, the need to improve endo-
vascular materials has arisen in order to increase the EVAR feasibility and to expand its indi-
cations (2). Moreover, the increased ability with the endovascular approach pushed many 
vascular specialists to use EVAR off-label, outside the instructions for use (IFU), especially in 
high-risk patients who are ineligible for conventional surgery (3, 4). Herein we report our ex-
perience with the Endurant II (Medtronic) stent-graft used under IFU and off-label in high-
risk patients considered unsuitable for conventional surgery. 
Methods
Single-center data of patients who underwent EVAR from December 2012 to March 2015 
were analyzed retrospectively. All data, including demographics, clinical and diagnostic 
preoperative assessments, intraoperative features, early (30-day) and late follow-up results, 
were prospectively collected and inserted into standardized piloted forms. Informed con-
sent was obtained from all patients for the procedure itself, anonymous data collection, and 
analysis.
Patients treated by standard EVAR with the Endurant II (Medtronic) stent-graft were 
screened and included in the study. Inclusion criteria consisted of infrarenal aorto-iliac 
pathology treated by a standard combination of Endurant II (Medtronic) stent-graft im-
plantation (including a bifurcated main body, a contralateral limb, and eventually limb 
extensions). 
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PURPOSE 
We aimed to compare the outcomes of the Endurant II (Medtronic) stent-graft used under in-
structions for use versus off-label in high-risk patients considered unfit for conventional surgery.
METHODS
Data from patients treated with the Endurant II stent-graft between December 2012 and March 
2015 were retrospectively analyzed. Sixty-four patients were included. Patients were assigned to 
group A if treated under instructions for use (n=34, 53%) and to group B if treated off-label (n=30, 
47%). Outcome measures included perioperative mortality and morbidity, survival, freedom from 
reintervention, endoleak incidence, in-hospital length of stay, and mean stent-graft component 
used. Mean follow-up was 22.61±12 months (median, 21.06 months; range, 0–43 months).
RESULTS
One perioperative mortality (1.6%) and one perioperative complication (1.6%) occurred in group 
B. At two months follow-up, one iliac limb occlusion (1.6%) occurred in group A. No type I/III en-
doleaks were recorded. A type II endoleak was identified in three cases (4.7%). Overall survival at 
three years was 89% (97% for group A, 82% for group B; P = 0.428). Reintervention-free survival 
at three years was 97% for both groups (P = 0.991). A longer in-hospital stay was observed in 
group B (P = 0.012).
CONCLUSION
The Endurant II (Medtronic) new generation device was safe in off-label setting at mid-term fol-
low-up. The off-label use of the Endurant II (Medtronic) is justified in patients considered unfit for 
conventional surgery. Larger studies are required in this subgroup of patients. 
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Exclusion criteria consisted of addition-
al tools to preserve renal and/or visceral 
patency; combined use of thoracic and ab-
dominal devices; combined use of Endurant 
II (Medtronic) component with other fabric 
stent-graft; and nonelective repair using 
EVAR (for symptomatic or ruptured AAA). 
A total of 64 patients with a mean age 
of 75.5±8 years (range, 60–93 years) were 
included. Patients were divided into two 
groups according to Endurant II (Medtron-
ic) manufacturer’s IFU (on-label vs off-la-
bel). Group A included 34 patients (53%) 
treated by on-label EVAR according to IFU 
(adequate iliac/femoral access that is com-
patible with vascular access techniques, 
devices and/or accessories; proximal neck 
length of ≥10 mm; infrarenal neck angula-
tion of ≤60°; distal fixation length of ≥15 
mm; aortic neck diameters with a range of 
19 to 32 mm; iliac diameters with a range 
of 8 to 25 mm; and morphology suitable for 
aneurysm repair). Group B included 30 pa-
tients (47%) presenting at least one char-
acteristic outside the IFU. Only patients 
considered at high-risk for conventional 
surgery were treated by off-label EVAR (5). 
The minimum anatomical requirements 
for off-label EVAR in group B were aor-
tic neck length ≥7 mm; maximum neck 
diameter ≤36 mm; and neck angulation 
≤90° (Fig. 1). All the preoperative anatomic 
assessments were performed on comput-
ed tomography angiography (CTA). CTAs 
were analyzed manually and with Endosize 
software (Therenva); discrepancies were 
solved through discussion. 
Primary outcomes analyzed were periop-
erative mortality and morbidity. Second-
ary outcomes were EVAR limb occlusion, 
survival, freedom from reintervention, en-
doleak incidence, in-hospital length of stay, 
and the mean number of stent-graft com-
ponents used. Procedure duration, contrast 
medium usage, and fluoroscopy time were 
also analyzed. 
The follow-up protocol consisted of CTA 
at 1, 6, 12 months and yearly thereafter for 
both groups. In case of CTA contraindication 
during the follow-up, unenhanced CT and 
duplex ultrasonography were combined 
(eventually with contrast enhancement).
Statistical analysis
Data analysis was performed using SPSS 
16.0 (SSPS Inc.). Statistical significance was 
assigned at two-sided P < 0.05. Baseline 
characteristic differences between groups 
A and B were assessed with one-way anal-
ysis of variance. Differences between the 
groups were assessed using the t test for 
continuous variables and the chi-square 
test for categorical variables. Kaplan-Meier 
curves were used to estimate survival and 
freedom from reinterventions; standard 
error exceeding 10% was reported. Differ-
ences in curves were assessed using the 
Brelow test.
Results
At baseline, group B had a significantly 
higher prevalence of coronary artery dis-
ease (15% vs. 10%, P = 0.042) and chronic 
pulmonary obstructive disease (46% vs. 
27%,  P = 0.050) (Table 1).
Main points
• Endovascular aneurysm repair (EVAR) is 
the first line approach in abdominal aortic 
aneurysm (AAA)  treatment and the need to 
improve endovascular materials has arisen in 
order to increase the EVAR feasibility and to 
expand its indications.
• Anatomic limitations of EVAR have been 
historically identified as hostile neck, iliac 
tortuosity, and access. 
• The increased ability with this tool have 
pushed many vascular specialists to use 
EVAR off-label, outside the instructions for 
use, especially in high-risk patients with AAA 
considered unfit for conventional surgery. 
• In this study, patients treated off-label 
presented a significantly larger aneurysm 
neck diameter and aneurysm sac diameter; 
a significantly shorter neck length, a higher 
proximal infrarenal neck angulation and a 
higher incidence of conical neck. 
• No differences were detected in mortality, 
morbidity, adjunctive intraoperative maneuvers, 
type Ia endoleak, three-year survival, and three-
year freedom from reintervention rates.
• The off-label use of the Endurant (Medtronic) 
stent-graft is an additional tool in the 
treatment of patients presenting with 
AAA that are considered unsuitable for 
conventional surgery.
Figure 1. a, b. Intraoperative angiogram of an 80-year-old man treated with off-label use. Angiogram 
(a) shows a 7 mm neck length and a positioned (undeployed) stent-graft. The left renal artery is 
lower than the right. The arrow shows the stent-graft positioned just below the left renal artery. Final 
angiogram (b) shows complete proximal sealing and regular patency of the lowest renal artery (left). 
The stent-graft is deployed just below the left renal artery (arrow).
a b
Preoperative anatomic findings showed a 
significantly larger aneurysm neck diameter 
at 10 mm below the lowest renal artery (or 
above aneurysm sac origin) in group B (30.6±6 
mm vs. 29.6±4 mm, P = 0.024). Aneurysm sac 
diameter was significantly higher in group 
B (65.8±21 mm vs. 60.1±15 mm, P = 0.030). 
Neck length was significantly shorter in group 
B (18±6 mm vs. 23.4±4 mm, P < 0.001) and 
the proximal infrarenal neck angulation was 
significantly higher in group B (38.8°±20° vs. 
28.4°±12°, P = 0.006). A higher percentage of 
patients in group B presented a conical neck 
(76.7% vs. 47.1%, P = 0.054) (Table 2).
Perioperative mortality was registered in 
one patient (1.6%) in group B. This patient 
was transferred to the ward after an uncom-
plicated EVAR procedure. After three hours 
he suffered from acute chest and abdomi-
nal pain and suddenly died. No autopsy was 
available for this patient.
No adjunctive intraoperative maneuvers 
were required in groups A or B. A perioper-
ative complication requiring reintervention 
occurred in one patient (1.6%) in group B. 
In this case, a right access surgical revision 
was required for a lymphatic fistula. Iliac 
limb occlusion occurred at two months in 
a patient from group A due to iliac stent-
graft kinking; this was managed with fem-
oro-femoral crossover.
At a mean follow-up of 22.61±12 months 
(median, 21.06 months; range, 0–43 months), 
neither type I nor type III endoleaks were 
recorded postoperatively or during the fol-
low-up. A type II endoleak occurred in three 
patients (4.7%): one patient in group A and 
two patients in group B (P = 0.486). 
The three-year overall survival was 89% 
with no statistically significant difference 
between the two groups (97% for group A 
vs. 83% for group B; P = 0.428) (Fig. 2). Over-
all, the estimated intervention-free surviv-
al was 97% with no statistically significant 
differences between the groups (P = 0.991) 
(Fig. 3). During the follow-up, four deaths 
occurred. The cause of death was not relat-
ed to the aortic pathology in these patients 
(malignancy in three patients and cerebral 
stroke in one).
Mean length of stay in the hospital was 
6±5 days (median 6 days; range, 3–24 days). 
Length of stay was significantly longer in 
group B compared with group A (8±6 days, 
median 7 days, range 3–18 days vs. 5±4 days, 
median 6 days, range 3–13 days; P = 0.012).
Mean number of component graft used 
per patient was 2.5±2 (range, 2–4) in group 
A and 2.9±3 (range, 2–5) in group B (P = 
0.118). No cuff extensions were employed 
in either group.
Mean procedure duration for groups A 
and B was 163±37 min and 189±69 min, 
respectively (P = 0.033); mean contrast me-
dium usage was 95±18 mL and 118±24 mL, 
respectively (P = 0.169); fluoroscopy time 
was 21±7 min and 27±9 min, respectively 
(P = 0.044).
Discussion
In our experience with the Endurant II 
(Medtronic) stent-graft used to treat AAAs 
under IFU vs. off-label, no difference was 
observed in perioperative mortality and 
morbidity. During the follow-up, no type I/III 
endoleaks were registered in either group. At 
three-year follow-up, no significant differenc-
es in terms of survival and intervention-free 
survival were recorded. A significantly longer 
in-hospital length of stay, mean procedure 
duration and fluoroscopy time were reported 
for patients treated off-label.
The Endurant (Medtronic) stent-graft was 
introduced in 2008 with the aim to over-
come anatomic limitations of concurrent de-
vices and expand EVAR indications (6), since 
patients presenting with unfavorable anato-
my had more-comorbidity and thus were at 
higher risk for conventional surgery (7, 8).
Anatomic limitations of EVAR have been 
historically identified as hostile neck, iliac 
tortuosity, and difficult access. While the iliac 
tortuosity and access can be overcome using 
special techniques (e.g., iliac conduit), hostile 
neck still remains as the most relevant issue 
with 20% of AAA presenting with inade-
quate neck for EVAR procedures (9, 10).
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Table 1. Comorbidities and risk factors of patients treated by on-label (group A) and off-label (group B) 
use of Endurant
 Group A Group B P
No. of patients 34 (53) 30 (47) 
Age (years), mean 75.1 76.1 0.613
Hypertension 28 (82) 28 (93) 0.254
Diabetes 7 (21) 4 (13) 0.518
Lipid disorder 13 (38) 11 (37) 0.993
CAD 10 (29) 15 (50) 0.042
CVD 5 (15) 9 (30) 0.224
PAD 4 (12) 1 (3) 0.357
COPD 9 (27) 14 (46) 0.050
Smoke 18 (53) 21 (70) 0.219
RFI 3 (9) 5 (17) 0.448
Malignancy 3 (9) 1 (3) 0.609
Data are presented as n (%) unless otherwise noted.
CAD, coronary artery disease; CVD, cerebrovascular disease; PAD, peripheral arterial disease; COPD, chronic obstructive 
pulmonary disease; RFI, renal function impairment.
Table 2. Preoperative anatomic findings of patients treated by on-label (group A) and off-label (group B) 
use of Endurant
 Group A Group B 
 n=34 n=30 P
Neck diameter at lowest renal artery (mm)  23.8±3 (18–28) 24±5 (16–33) 0.121
Neck diameter at 10 mm below or above the  29.6±4 (18–28) 30.9±6 (16–36) 0.024 
aneurysm sac (mm) 
Aneurysm sac maximal diameter (mm) 60.1±15 (50–120) 65.8±21 (52–110) 0.030
Aortic bifurcation diameter (mm) 32±9 (21–63) 33.3±10 (18–64) 0.550
Neck length (mm) 23.4±4 (12–26) 18±6 (7–22) <0.001
Proximal infrarenal neck angulation (°) 28.4±12 (4–60) 38.8±20 (15–85) 0.006
Conical infrarenal neck, n (%) 16 (47.1) 23 (76.7) 0.054
Data are presented as mean±standard deviation (range) unless otherwise noted.
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EVAR outcomes in patients presenting 
with hostile neck show higher complica-
tion rates such as type Ia endoleak. Thus, 
most authors suggest cautious off-label 
use of stent-graft, only in high-risk surgical 
patients (4). Despite the advocated caution 
in treating patients outside the manufac-
turer’s IFU, almost one-third of patients are 
currently treated off-label (11). Results from 
the Endurant Stent Graft Natural Selection 
Global Postmarket Registry, showed that 
intra-operative hostile neck (length and 
thrombus/calcification) was related to a 
higher incidence of adverse events com-
pared with adequate neck (12). 
In a recent meta-analysis of 1559 patients, 
Antoniou et al. (3) reported that there is no 
high-level evidence to demonstrate the 
off-label use of stent-graft as safe. Thus they 
recommended a cautious use of off-label 
EVAR and only in high-risk patients. The 
study outcomes showed a significantly 
higher incidence of adjunctive maneuvers, 
perioperative morbidity, endoleak inci-
dence and mortality at one-year in patients 
treated with off-label EVAR. No significant 
differences were reported in technical suc-
cess, perioperative mortality, perioperative 
reinterventions, perioperative endoleaks, 
and one-year reintervention rate. As argued 
by the same authors, the higher incidence 
of type Ia endoleak was not followed by a 
reintervention and this could explain the 
higher one-year mortality. However, this 
meta-analysis included studies with old 
generation devices and different fabrics. 
Recent studies focused on the feasibility 
and the outcomes of Endurant II (Medtron-
ic) used off-label. These studies also report-
ed a higher incidence of type Ia endoleak 
and iliac limb occlusion for off-label stent 
use compared with patients treated under 
IFU (13–15). 
Fenestrated and branched EVAR (F/BEV-
AR) (16, 17) and chimney and periscope 
EVAR (ch-EVAR) (18, 19) have been intro-
duced to overcome these anatomic limita-
tions with good results even in emergent 
settings (20). Moreover, ch-EVAR can be em-
ployed with good results in the treatment 
of type Ia endoleak after standard EVAR 
(21). However, these tools require high en-
dovascular skills and have a higher cost. In 
our experience, we registered one case of 
perioperative mortality among patients 
treated with off-label EVAR; in this case no 
amenable cause of death was recognized 
and autopsy was not available. In our study 
we did not encounter any type Ia endoleaks, 
but type II endoleak occurred in three cas-
es. It can be proposed that the absence of 
type I endoleak (especially in group B) can 
be justified by the limited patient sample. 
However, the new generation device that 
we employed could also play a role in the 
reduced type Ia endoleak incidence in pa-
tients treated with off-label EVAR. A longer 
mean procedure duration and fluorosco-
py time was reported in patients treated 
off-label. We can speculate that the need 
for a more accurate projection before the 
Figure 2. Estimated survival function. Standard error (SE) exceeds 10% at 24 months for overall curve; 
SE does not exceed 10% at 36 months for on-label treatment; SE exceeds 10% at 2 months for off-
label use. No significant differences were observed between the curves (P = 0.428).
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Figure 3. Estimated freedom from reintervention. SE does not exceed 10% at 36 months for all 
curves. No significant differences were observed between the curves (P = 0.991).
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stent-graft deployment (shorter neck and 
higher neck angulation) could be related to 
these outcomes. Despite this, contrast me-
dium usage was not significantly greater in 
patients treated off-label. 
Retrospective analysis, small sample size 
and lack of randomization represent major 
limitations of this study. However, the use 
of new generation device yields supportive 
evidence for off-label use in patients con-
sidered unfit for conventional surgery. 
In conclusion, the Endurant II (Medtron-
ic) new generation device was safe in our 
single-center experience even when em-
ployed in an off-label setting at mid-term 
follow-up. No differences in outcomes 
were evident between the group treated 
under IFU and the group treated off-label. 
The off-label use the Endurant (Medtronic) 
stent-graft represents an additional tool in 
the treatment of patients presenting with 
AAA that are considered unfit for conven-
tional surgery. More extensive experience is 
required in this subgroup of patients.
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